ADC Therapeutics (ADCT) Change in Accured Expenses (2023 - 2026)

ADC Therapeutics has disclosed Change in Accured Expenses across 4 years of filings, most recently posting -$3.2 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$3.2 million, up 84.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.0 million (up 268.59% YoY), and the FY2025 annual result was -$7.4 million, down 166.61% from the prior year.
• Change in Accured Expenses came in at -$3.2 million for Q1 2026 at ADC Therapeutics, down from $2.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $12.0 million in Q2 2025 to a low of -$20.6 million in Q1 2025.
• The 4-year median for Change in Accured Expenses is -$799000.0 (2025), against an average of -$1.0 million.
• Across the five-year window, Change in Accured Expenses jumped 1172.64% in 2024 and slumped 482.3% in 2025, its largest moves.
• ADC Therapeutics' Change in Accured Expenses stood at $2.0 million in 2023, then jumped by 475.61% to $11.3 million in 2024, then slumped by 82.54% to $2.0 million in 2025, then slumped by 261.25% to -$3.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.2 million (Q1 2026), $2.0 million (Q4 2025), and -$799000.0 (Q3 2025), per Business Quant data.